Sundrug - Public Comps and Valuation Multiples

Sundrug Overview

About Sundrug

Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.

Founded

1965

HQ

Employees

16.5K+

Website

sundrug.co.jp

Sectors

Pharmacies

Financials

LTM Revenue $5.5B

LTM EBITDA $428M

EV

$3.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sundrug Financials

As of September 2025, Sundrug reported last 12-month revenue of $5.5B and EBITDA of $428M.

In the same period, Sundrug generated $588M in LTM gross profit and $211M in net income.

See Sundrug valuation multiples based on analyst estimates

Sundrug P&L

In the most recent fiscal year, Sundrug reported revenue of $5.3B and EBITDA of $404M.

Sundrug expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sundrug valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$5.5B	XXX	$5.3B	XXX	XXX	XXX
Gross Profit	$588M	XXX	$1.4B	XXX	XXX	XXX
Gross Margin	11%	XXX	25%	XXX	XXX	XXX
EBITDA	$428M	XXX	$404M	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBIT	$309M	XXX	$295M	XXX	XXX	XXX
EBIT Margin	6%	XXX	6%	XXX	XXX	XXX
Net Profit	$211M	XXX	$204M	XXX	XXX	XXX
Net Margin	4%	XXX	4%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sundrug including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $5.5B. EBITDA for the last twelve months was $428M. In the most recent fiscal year, Sundrug achieved $5.3B in revenue and $404M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$5.5B	Analyst estimates available to subscribers	$5.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$588M	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	10.7% gross margin	Analyst estimates available to subscribers	25.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$428M	Analyst estimates available to subscribers	$404M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	7.7% EBITDA margin	Analyst estimates available to subscribers	7.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$309M	Analyst estimates available to subscribers	$295M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	5.6% EBIT margin	Analyst estimates available to subscribers	5.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$211M	Analyst estimates available to subscribers	$204M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	3.8% net profit margin	Analyst estimates available to subscribers	3.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sundrug

This financial data table provides comprehensive performance metrics for Sundrug, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sundrug generated $5.5B in revenue over the last twelve months.
The company achieved $428M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $588M.
Net income over the last twelve months reached $211M.

Fiscal Year Performance

In the most recent fiscal year, Sundrug reported $5.3B in total revenue.
Fiscal year EBITDA was $404M.
The company maintained a gross profit margin of 25.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 7.6%.
Net profit margin reached 3.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sundrug. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sundrug Stock Performance

Sundrug has current market cap of JPY 479B (or $3.2B), and EV of JPY 460B (or $3.0B).

Market Cap Evolution

Sundrug Stock Data

As of October 30, 2025, Sundrug's stock price is JPY 4092 (or $27).

See Sundrug trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.0B	$3.2B	XXX	XXX	XXX	XXX	$1.80

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sundrug Valuation Multiples

Sundrug's trades at 0.6x EV/Revenue multiple, and 7.7x EV/EBITDA.

See valuation multiples for Sundrug and 15K+ public comps

Sundrug Financial Valuation Multiples

As of October 30, 2025, Sundrug has market cap of $3.2B and EV of $3.0B.

Equity research analysts estimate Sundrug's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sundrug has a P/E ratio of 15.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.2B	XXX	$3.2B	XXX	XXX	XXX
EV (current)	$3.0B	XXX	$3.0B	XXX	XXX	XXX
EV/Revenue	0.6x	XXX	0.6x	XXX	XXX	XXX
EV/EBITDA	7.1x	XXX	7.7x	XXX	XXX	XXX
EV/EBIT	9.9x	XXX	10.5x	XXX	XXX	XXX
EV/Gross Profit	5.2x	XXX	n/a	XXX	XXX	XXX
P/E	15.0x	XXX	15.8x	XXX	XXX	XXX
EV/FCF	58.0x	XXX	77.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sundrug Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sundrug Margins & Growth Rates

Sundrug's last 12 month revenue growth is 8%

Sundrug's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Sundrug's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sundrug's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sundrug and other 15K+ public comps

Sundrug Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	8%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	8%	XXX	8%	XXX	XXX	XXX
EBITDA Growth	8%	XXX	9%	XXX	XXX	XXX
Rule of 40	15%	XXX	15%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	27%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	20%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial